Executive Narrative - Henry Schein, Inc. achieved the highest sales growth in 15 quarters, driven by the effective execution of the BOLD+1 strategic plan and recovery from previous cybersecurity disruptions [4] - High-growth, high-margin businesses now account for nearly 50% of total operating income, indicating a strategic shift towards specialty products and technology solutions [4] - Global dental equipment sales reached record levels, with double-digit growth in traditional equipment and market share gains from technical service capabilities [4] Sales and Market Performance - U.S. dental merchandise growth was supported by data-driven marketing initiatives and increased procedure volumes, as indicated by Henry Schein One eClaims activity [4] - The Global Technology segment saw a 20% year-over-year increase in cloud-based subscribers, exceeding 11,000 Dentrix Ascend users globally [4] Strategic Initiatives - Strategic partnerships with Amazon Web Services are integrating generative and agentic AI into practice management systems to automate administrative workflows and clinical documentation [4] - Management attributes recent success to a shift from internal recovery efforts back to aggressive market engagement and sales force expansion [4] Future Projections - Sales growth for 2026 is projected at 3% to 5%, assuming stable dental and medical end markets and consistent foreign currency exchange rates [4] - Earnings growth is expected to be more heavily weighted towards the second half of 2026 as value creation initiatives reach full implementation [4] - Value creation projects are targeted to deliver over $125 million in annual run-rate operating income improvement by the end of 2026 [4] E-commerce and Restructuring - The rollout of the new henryschein.com e-commerce platform is scheduled for completion for U.S. dental and Canadian customers in Q1 2026 [4] - The company recorded $105 million in total restructuring expenses for the full year 2025 related to the program announced in August 2024 [4] Market Challenges - U.S. medical sales face headwinds from lower comparative demand in respiratory products and vaccinations following post-pandemic normalization [6] - Management indicated that potential tariff impacts can be mitigated through alternative sourcing and passing costs through to customers [6]